MedTrace Logo

Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis and Pseudomonas Aeruginosa Airway Infection

NCT00499720 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2011-08-02

No results posted yet for this study

Summary

The primary objective of this program is to provide expanded access to aztreonam lysine for inhalation (AZLI) 75 mg prior to its commercial availability to patients with cystic fibrosis (CF) and chronic P. aeruginosa airway infection who have limited treatment options and are at risk for disease progression.

Conditions

Interventions

DRUG

Aztreonam Lysine for Inhalation

75 mg three times a day via inhalation for 28 days followed by 28 days off drug.

Sponsors & Collaborators

Eligibility

Min Age
6 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00499720 on ClinicalTrials.gov